NCT03574571 2026-02-27
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 3 Active not recruiting
Clinical Trials
13 trialsNCT05133440 2026-01-21
A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05924672 2026-01-14
Efficacy of Ra-223 in PSMA PET Optimally Selected Patients
University of California, San Francisco
Phase 2 Active not recruiting
NCT04037358 2025-12-19
RAVENS
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03737370 2025-10-07
Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer
Tufts Medical Center
Phase 1 Completed
NCT02194842 2025-09-19
PEACE III
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Active not recruiting
NCT05383079 2025-02-07
AlphaBet
Peter MacCallum Cancer Centre, Australia
Phase 1/2 Active not recruiting
NCT03002220 2024-12-11
EXCAAPE
MedSIR
Phase 2 Completed
NCT03230734 2024-09-27
RAPSON
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Active not recruiting
NCT03432949 2024-01-24
TRANCE
University Health Network, Toronto
Phase 4 Unknown
NCT05771896 2023-09-14
CARE
GenesisCare USA
Phase 3 Withdrawn
NCT02278055 2023-04-07
Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02225704 2023-04-06
Radium-223 in Combination With Enzalutamide
Cancer Trials Ireland
Phase 2 Completed